Neomycin (Fml-neo Liquifilm Ophthalmic)
Neomycin
Abbvie (Pty) Ltd
Registration
- Applicant
- Abbvie (Pty) Ltd
- Certificate holder
- Abbvie (Pty) Ltd
- Registrations
- 1
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Fml-neo liquifilm ophthalmic suspension EACH 1 ml OPHTHALMIC SUSPENSION CONTAINS FLUOROMETHOLONE 1,1 mg NEOMYCIN SULPHATE EQUIVALENT TO 3,85 mg/ml NEOMYCIN | 1,0 mg/mlOphthalmic suspension | J0335J/15.2/335Approved 3 September 2024 | Registered | Not determined | PIPIL |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Fluorometholone
Consolidated Schedules 06 July 2026, line 6384
S4: Neomycin
- except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947).
Consolidated Schedules 06 July 2026, lines 7224 to 7225
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
(2R,3S,4R,5R,6R)-5-Amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-4-[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol
Drag to rotate. Structure from PubChem CID 8378.
SAHPRA documents
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.